EVERSANA COMPLETE Commercialization®
A Comprehensive, Customizable Life Sciences Commercialization Model
Even though pharma companies spend more than $125 million over the three years leading up to a drug’s launch, 66% of launches don’t meet expectations. Financial risk, industry pressures and unforeseen complexities are forcing developers and investors to seek advanced commercialization options that maximize their pipelines.
EVERSANA COMPLETE Commercialization®, an award-winning model that is disrupting the pharma industry, offers an alternative to selling, out-licensing or launching internally.
Article
EVERSANA COMPLETE COMMERCIALIZATION® is helping pharma companies achieve flexible, agile product launches that meet client and patient needs.
To optimize global drug launches, developers can choose between a comprehensive end-to-end outsourcing strategy or a flexible, just-in-time infrastructure. EVERSANA COMPLETE, now in its fifth year, offers both options and has improved efficiency, cost savings, patient outcomes, and risk management.
Read the article by Greg Skalicky and Jennifer Meeuwsen to learn more about the benefits and real-world applications of this approach.
READ NOWPharma Commercial Solutions for Every Company and Phase
EVERSANA’s life sciences commercialization model enables flexible, agile product launches tailored to client and patient needs. Our proactive team monitors market conditions and program readiness, ensuring swift course corrections. Our integrated systems and culture facilitate quick mobilization and efficient communication, enhancing customer experience while minimizing operational and financial risks for our partners – of any size and at any phase.
A Full-Scale Launch Model for Emerging Pharma
- Affords investors full access to a complete, end-to-end commercialization model
- Delivers more value than traditional licensing or launching on your own
- Activates ready-to-deploy, high-performance pharma commercial solutions and distribution engine
- Accelerates your product from early development to marketing, positively impacting patient outcomes
- Mitigates risk and combats curveballs that manufacturers cannot predict when launching products
A Customized Commercialization Model for Oncology Therapies
- Offers an integrated platform of commercialization services provides fit-for-purpose solutions to support oncology therapy commercialization
- Leverages data-driven solutions to account for smaller patient populations, evolving patient journeys and interactions with the FDA
- Maximizes and compliments existing internal resources to effectively manage go-to-market strategies
- Provides exclusive access to an established infrastructure, networks and expertise in the oncology market that may not be available in-house
A Life Cycle Management Model for Established Brands
- Eliminates capability and capacity restraints to increase the throughput of in-licensed assets
- Serves as a catalyst for biopharma companies to address the management of their established brand portfolios
Proven and Predictable Commercial Success
Complete, full-scale, customizable infrastructure amplified by top industry launch leaders
- Optimize the launch of precommercial assets
- Capture full revenue potential through maturity
Revolutionary, nontraditional financial deal structures that provide flexibility of terms and options
- Provides an alternative to traditional and more common strategies, such as selling, out-licensing or going at it alone
- Reduces upfront cash investments necessary to launch
- Maximizes revenue potential and minimizes financial risk
Integrated, predictive and actionable data to maximize growth potential
- Maximizes the ROI of data and analytics investments
- Enhances decision-making
- Creates a seamless patient journey and positively impacts outcomes
Empowering Collaboration: How EVERSANA Serves as an Extension of Your Team for Maximum Control and Success
Sharon Cunningham, co-founder and CEO of Shorla Oncology, is a visionary leader who understands the importance of strategic partnerships in propelling Shorla’s mission forward. Sharon shares invaluable insights gleaned from her experience, shedding light on the key factors that contribute to successful collaborations in the pharmaceutical arena.
Learn more about our recent partnerships.
Case Studies: Real-World Impact
Leveraging our data and analytics platform, our team works together to produce the best outcomes for our partners and their patients.
-
AGILITY
Our team is trained to proactively monitor market conditions, assess the commercial readiness of the program and course-correct in an agile manner.
View Case Study -
SPEED
Our integrated systems and culture allow us to mobilize the execution team quickly and communicate efficiently to create a positive customer experience.
View Case Study -
Risk Management
Our proven, ready-to-deploy commercialization model minimizes operational and financial risks for our partners.
View Case Study